In a transformative move, Alkermes completed its acquisition of Avadel Pharmaceuticals, adding a late‐stage sleep medicine franchise to its portfolio. This deal expands Alkermes’ commercial reach into Europe and North America, leveraging Avadel’s existing product registrations for once‐nightly formulation of sodium oxybate. Management projects the combined sleep medicine business to generate over $300 million in peak annual sales, capitalizing on cross‐selling opportunities and streamlined manufacturing synergies that could reduce COGS by as much as 15%.

Alkermes reported top‐line Vibrance‐2 data showing its orexin receptor agonist achieved a statistically significant increase in wakefulness maintenance compared to placebo, with a mean Improvement of 3.2 hours in the Maintenance of Wakefulness Test (MWT). The trial’s favorable safety profile—no treatment‐related serious adverse events in over 200 participants—reduces clinical risk for the pivotal registration program. Company guidance indicates a Phase 3 initiation within the next six months, positioning Alkermes as a potential leader in narcolepsy treatment.

Revenue contributions from Lybalvi and Vraylar continue to underpin Alkermes’ ambitious R&D agenda. Lybalvi sales grew 32% year-over-year, driven by expanded prescribing in major U.S. territories, while improved gross-to-net dynamics enhanced product margins by approximately 250 basis points. These profits are being channeled into four mid- to late-stage programs, including a novel injectable for schizophrenia and two neuroscience assets targeting mood disorders, with expected combined development expenditures exceeding $200 million over the next 12 months.

The U.S. Food and Drug Administration has awarded Breakthrough Therapy Designation to Alkermes’ alixorexton candidate for narcolepsy type 1 (NT1). This status follows positive Vibrance-1 data demonstrating rapid onset of action and significant reductions in excessive daytime sleepiness scores within two weeks of dosing. The designation enables accelerated development and rolling submission of the New Drug Application, potentially shortening the regulatory timeline by six to nine months and enhancing investor visibility on a mid-2025 commercialization target.